Clarivate Plc

Clarivate Plc (CLVT) Market Cap

Clarivate Plc has a market capitalization of $1.72B.

Financials based on reported quarter end 2025-12-31

Price: $2.68

-0.05 (-1.83%)

Market Cap: 1.72B

NYSE · time unavailable

CEO: Matitiahu Shem Tov

Sector: Technology

Industry: Information Technology Services

IPO Date: 2018-10-29

Website: https://www.clarivate.com

Clarivate Plc (CLVT) - Company Information

Market Cap: 1.72B · Sector: Technology

Clarivate Plc, an information services and analytics company, provides structured information and analytics for discovery, protection, and commercialization of scientific research, innovations, and brands. It offers Web of Science products and services, such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio to organizations that plan, fund, implement, and utilize research; and Life Sciences products, including Cortellis and Newport Integrity for pharmaceutical and biotechnology companies to support research, market intelligence, and competitive monitoring in connection with the development and commercialization of new drugs. The company also provides Derwent products, which include Derwent Innovation, Techstreet, and IP Professional Services that enables its customers to evaluate the novelty of potential new products, confirm freedom to operate with respect to their product design, help them secure patent protection, assess the competitive technology landscape, and ensure that their products comply with required industry standards; CompuMark products, such as trademark screening, searching, and watching products and services for businesses and law firms; and MarkMonitor products, which helps enterprises to establish, manage, optimize, and protect their online presence. It serves government and academic institutions, life science companies, and research and development corporations in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. The company was formerly known as Clarivate Analytics Plc and changed its name to Clarivate Plc in May 2020. Clarivate Plc is headquartered in London, the United Kingdom.

Analyst Sentiment

52%
Hold

Based on 9 ratings

Analyst 1Y Forecast: $3.60

Average target (based on 2 sources)

Consensus Price Target

Low

$3

Median

$3

High

$4

Average

$3

Potential Upside: 23.1%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 CLARIVATE PLC (CLVT) — Investment Overview

🧩 Business Model Overview

Clarivate PLC is a leading global provider of trusted information, analytics, and workflow solutions. Its core business addresses the needs of professionals in scientific and academic research, intellectual property (IP), and life sciences by aggregating, organizing, and curating complex datasets. These offerings are delivered through a portfolio of proprietary platforms and software tools, enabling customers to discover, protect, and commercialize ideas, inventions, and brands. Clarivate’s mission centers on empowering innovation by transforming intelligence into actionable insights across research, IP, and regulatory workflows. The business is built around subscription-based and recurring-revenue-driven models. Its platforms, including Web of Science, Derwent, and Cortellis, are widely used among universities, corporations, government agencies, and legal professionals. Through both organic growth and a track record of strategic acquisitions, Clarivate has amassed a broad client base and deep intellectual property, supporting defensive moats and cross-selling opportunities.

💰 Revenue Streams & Monetisation Model

Clarivate generates revenue primarily through subscriptions, licensing, and transaction-based services, underpinned by several key product families: - **Academic & Government**: Subscriptions to research analytics tools (such as Web of Science, ScholarOne) used by libraries, universities, and governmental bodies. - **Intellectual Property (IP) Solutions**: Access to patent and trademark databases, proprietary software for IP management, and professional services facilitating registration, research, and litigation support (notably Derwent and CompuMark). - **Life Sciences & Healthcare**: Workflow and intelligence solutions (such as Cortellis) that provide drug pipeline data, clinical trial information, regulatory guidance, and real-world evidence to pharmaceutical and biotech companies. - **Professional Services & Consulting**: Bespoke analysis, regulatory consulting, and knowledge management support, usually tailored to complex or large clients. Most revenues are recurring, with long-duration customer contracts fostering high visibility and cash flow stability. Pricing is typically value-based, reflecting the mission-critical nature and proprietary uniqueness of the datasets and analytics provided.

🧠 Competitive Advantages & Market Positioning

Clarivate’s competitive advantages stem from several sources: - **Deep, Proprietary Data Assets**: Decades of curated, structured, and frequently updated data form the backbone of its platforms, conferring significant barriers to entry. - **Strong Brand Equity**: Flagship offerings such as Web of Science and Derwent are recognized references in academia and IP circles, often embedded in institutional workflows. - **Switching Costs & Embedded Workflows**: Once integrated into customer processes, platforms are difficult to displace due to workflow customization, user training, and compliance dependencies. - **Scale & Network Effects**: Extensive client and data networks enable more comprehensive offerings and improved analytics, reinforcing value for both existing and prospective customers. - **Regulatory & Compliance Integration**: Many solutions help clients meet stringent regulatory and compliance obligations, further binding them to the Clarivate ecosystem. Competition exists from specialized data providers, public repositories, and large enterprise software companies, but few rivals match Clarivate’s breadth, data depth, or long-standing client relationships in its core verticals.

🚀 Multi-Year Growth Drivers

Clarivate’s long-term growth prospects are anchored by several durable trends: - **Rising Global Investment in R&D**: Academic research, IP creation, and drug development ecosystems continue to expand globally, driving demand for authoritative information solutions. - **Proliferation of Intellectual Property**: As innovation becomes central to economic growth, organizations place increasing value on patent, trademark, and regulatory intelligence. - **Digitization of Research & Regulatory Workflows**: Analog or manual processes are rapidly being replaced by integrated analytics and workflow tools—a domain where Clarivate excels. - **Emergence of Data-Driven Discovery & AI**: Growth in advanced analytics, AI-based discovery, and decision-support tools increases reliance on high-quality, well-structured datasets. - **Geographic Expansion & Cross-Selling**: Growth opportunities exist in underpenetrated regions and segments, supported by cross-selling richer product suites to the existing customer base. - **Strategic Acquisitions**: Acquisitive growth remains a strategic pillar, deepening product capabilities, expanding vertical reach, and increasing customer stickiness.

⚠ Risk Factors to Monitor

Investors should be aware of key risks that could affect Clarivate’s growth and profitability: - **Customer Budget Constraints**: Constrained budgets in academia or government may impact subscription renewals or pricing power, particularly during economic downturns. - **Integration and Execution Risks**: Acquisitions are integral to the company’s strategy, posing ongoing risks around integration, value realization, and cultural alignment. - **Data Privacy & Regulatory Exposure**: Handling sensitive research and IP data brings exposure to evolving international data privacy and security regulations. - **Competition & Technological Disruption**: Advances by competitors, emerging open-access initiatives, or disruptive technologies could erode market share or pricing power over time. - **Leverage and Capital Structure**: Use of debt to fund acquisitions increases financial leverage and interest expense, potentially reducing balance sheet flexibility.

📊 Valuation & Market View

Clarivate is generally valued as a specialized information services and analytics provider, often compared to peers in scientific research and intellectual property intelligence. Valuation multiples tend to reflect its recurring revenue profile, high margins, and strong free cash flow generation potential. However, integration risk from acquisitions and leverage can moderate premium multiples historically associated with data-centric businesses. Investor sentiment around Clarivate reflects recognition of its “picks and shovels” role in the global knowledge economy, balanced against execution risks in technology integration and the need to demonstrate consistent organic growth amid ongoing acquisition activity. Market participants may also weigh the defensiveness of end markets versus cyclicality in customer spending and regulatory environments.

🔍 Investment Takeaway

Clarivate PLC offers shareholders exposure to enduring secular trends in research, IP, and life sciences innovation worldwide. The company benefits from entrenched platforms, mission-critical datasets, and an attractive recurring-revenue model that provides high visibility and operating leverage. Its scale, brand recognition, and integrated workflow solutions create high switching costs, while multi-year growth is supported by increasing demand for data-driven decision-making, digitization, and global expansion. However, reliance on acquisitions, leverage, and customer concentration within education and life sciences presents ongoing risks. Sustainable value creation will require successful integration of acquired assets, disciplined capital allocation, continued product innovation, and nimble adaptation to regulatory and technological shifts. For long-term investors seeking a data-centric, “knowledge infrastructure” growth story with recurring revenue and a leadership position, Clarivate warrants considered due diligence within a diversified portfolio.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"As of Q4 2025, CLVT reported revenue of $617 million with net income of $3.1 million, translating to an EPS of $0.0047. The net margin stands at approximately 0.50%, and although free cash flow showed a strong figure at $352.4 million, this appears inconsistent with other cash flow metrics. Revenue growth appears tepid with no clear drivers of substantial growth. Profitability is marginal with a low net margin and EPS. Operating cash flow at $159.9 million versus capital expenditures of $192.5 million indicates challenges in sustaining positive cash flow solely from operations. The absence of dividend payments and a significant share price decline of over 40% in the past year highlight weak shareholder returns. CLVT's balance sheet shows a moderate leverage with total liabilities at $6.23 billion versus equity of $4.84 billion, and net debt standing at $4.15 billion. Valuation metrics indicated a bearish sentiment with the share price showing a downtrend, yet the consensus price target suggests some upside. Overall, CLVT faces profitability challenges, although the potential for appreciation based on analyst targets remains a point of speculation."

Revenue Growth

Neutral

Revenue of $617 million indicated flat or negative growth, lacking strong growth drivers or stability.

Profitability

Neutral

Minimal operating margins and low EPS at $0.0047 demonstrate inefficiency and weak earnings power.

Cash Flow Quality

Caution

Free cash flow is strong at $352.4 million, but inconsistency with operating and capex figures raises quality concerns.

Leverage & Balance Sheet

Fair

Moderately leveraged with liabilities of $6.23 billion against equity of $4.84 billion, with manageable financial resilience.

Shareholder Returns

Neutral

Total shareholder returns are poor with significant price declines and no dividends or buybacks.

Analyst Sentiment & Valuation

Neutral

Analyst sentiment suggests potential upside despite current bearish trends; valuation remains speculative.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Clarivate sounds confident on AI-enabled renewal durability and cash generation, but the Q&A and guidance mechanics expose near-term lumpiness and execution risk. Management repeated that subscription pricing is primarily institution-size based, but did not provide a quantitative seat-license share (despite the question), instead emphasizing “hardening” renewals via AI features. The most concrete operational hurdles were timing-related: Q1 is expected to be essentially flat for recurring organic revenue because prior-year U.S. patent renewal accelerations unwind in the first half, and “transactional books revenue will cease this summer,” creating a step down from H1 to H2. On strategy risk, the LS&H sale process is active with interested parties but explicitly has “no guarantees,” while 2026 guidance assumes LS&H is owned for the full year—leaving room for later guidance revisions. Despite a +200 bps EBITDA margin target at midpoint and ~$400M FCF, the question-and-answer pressure highlights transition execution and seasonality rather than purely demand growth.

AI IconGrowth Catalysts

  • AI assistant + AI workflow agents embedded in customer workflows (tasks in minutes vs hours/days)
  • Nexus ecosystem access: embeds Web of Science curated content into public chat tools
  • A&G: 10 AI assistants / AI-native agentic solutions deployed to 4,000+ institutions
  • IP: rollout of 5 GenAI + AI-native product launches in 2025; additional AI launches across IP in 2026
  • Life Sciences & Health: adoption to 11,000 global active users; release of 10+ additional AI solutions in 2026

Business Development

  • Launched process to sell Life Sciences & Health (Cortellis, DRG and other major product lines referenced) via strategic alternative review; active discussions with interested parties (no agreement guarantee stated)
  • A&G/IP synergy mentioned through shared content assets and technology platform (specific unnamed university tech transfer accounts; "major universities" taking over annuity business and expansions in U.S.)
  • Matti explicitly declined to name customers; stated capability to "take over the annuity business" for top U.S. universities without naming them

AI IconFinancial Highlights

  • Q4 revenue: $617M (full-year revenue: $2.455B); Q4 net income: $3M
  • Adjusted diluted EPS: $0.20 in Q4 (up $0.02 sequentially; increase vs prior year described as driven by noncash impairment non-recurrence and lower tax/interest)
  • Free cash flow: Q4 $89M; full-year $365M (toward high end of guidance; ~2% growth vs prior year)
  • Operational margin: Q4 profit margin run-rate just over 41% (about +50 bps vs full-year results)
  • 2025 sales/execution: nearly 2% organic ACV growth at high end; ~90 bps year-over-year improvement attributed to sales execution
  • IP performance: +270 bps year-over-year improvement in annuities revenue (stronger execution)
  • 2026 guidance (midpoint): organic annual contract value (ACV) growth 2%–3%; recurring organic growth ~1.5% (nearly +100 bps vs last year midpoint); revenue decline to ~$2.36B midpoint (~-$100M vs prior year midpoint) due to divestiture wind-down; adjusted EBITDA margin expansion ~+200 bps to ~43% midpoint; diluted adjusted EPS ~$0.75 (~+9% at midpoint); free cash flow ~$400M (~+10% at midpoint)
  • Foreign exchange translation benefit assumed: ~$10M top-line and ~$5M bottom-line in 2026
  • Tax/capital items impacting cash taxes: expected cash taxes +$5M to +$10M due largely to new corporate tax in Jersey

AI IconCapital Funding

  • Share repurchases: $225M buyback in 2025
  • Debt: called $100M of bonds due later in 2025 and called remaining $100M in Jan 2026
  • Net leverage maintained at ~4 turns while retiring $56M (~7%) of outstanding shares
  • Repurchase impact: lowered share count by ~13% (cited for 4-year period) and may generate additional balance-sheet strengthening proceeds if LS&H sale closes

AI IconStrategy & Ops

  • Value creation plan emphasis: portfolio simplification; strategic review initiated late 2024; launched process to sell LS&H
  • Business model optimization: improved organic recurring revenue mix to 88% in 2025; A&G recurring mix to 93% (mid-90s retention rates) cited
  • Product cadence: 12 major products + AI-powered features introduced in 2025; 10 AI assistants/agentic solutions in A&G; 5 GenAI/AI-native IP products/enhancements in 2025; LS&H to release 10+ more AI solutions in 2026
  • Q1/seasonality timing hurdles: expected slight sequential pullback in Q1 (renewal timing); recurring organic revenue essentially flat in Q1 (patent renewal accelerations in U.S. unwind in first half); transactional books revenue to cease this summer causing a step down from H1 to H2

AI IconMarket Outlook

  • 2026 organic ACV growth: 2%–3%
  • 2026 recurring organic growth: ~1%–2% (midpoint ~1.5%)
  • 2026 free cash flow: ~$400M at midpoint (~+10%)
  • 2026 adjusted EBITDA margin: nearly 43% at midpoint; expansion ~+200 bps at midpoint
  • 2026 revenue midpoint assumption: ~$2.36B (decline almost $100M midpoint) due to divestiture wind-down; guidance explicitly assumes LS&H owned for full year (potential revision later if sale agreement reached)

AI IconRisks & Headwinds

  • Divestiture execution uncertainty: LS&H sale process has "no guarantees" and guidance assumes ownership for full year; revision could come later in year if agreement is reached
  • Timing-driven near-term revenue/profile pressure: Q1 sequential pullback due to renewal timing differences; recurring organic revenue essentially flat in Q1 due to patent renewal accelerations not recurring this year
  • Transactional book revenue discontinuity: transactional books revenue ceases "this summer" causing sequential step down from first to second half, though company expects margin benefit
  • Operational constraint called out in guidance discussion: transactional/subscription mix impacts; Q4 organic subscription +1% but total organic revenue down ~1% due to offsetting recurring vs transactional mix shift

Sentiment: MIXED

Note: This summary was synthesized by AI from the CLVT Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (CLVT)

© 2026 Stock Market Info — Clarivate Plc (CLVT) Financial Profile